FindTrial
Sign In

To study the effects of anti fungal treatment of a subset in CLL patients harboring stereotypic receptors with high specificity for yeasts and molds.

To study the effects of anti fungal treatment of a subset in CLL patients harboring stereotypic receptors with high specificity for yeasts and molds. - posaconazole Study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36874
Enrollment
3
Registered
2012-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posaconazole

Interventions

Patients have to take 3 times daily one tablet of posaconazole for a period of six weeks

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Diagnosis of CLL / MBL with mutated IGHV3-7 rearrangements paired to IGKV2-24 encoded light chains; * Age 18-80 years * No CLL related treatment during the last 3 months; * Able to adhere to the study visit schedule and other protocol requirements; * WHO performance status of * 2; * Laboratory test results within these ranges: absolute neutrophil count * 1.0 x 109/l, platelet count * 30 x 109/l, creatinine clearance * 60 ml/min, total bilirubin * 25 µmol/L, AST & ALT * 2 x ULN; * Written informed consent.

Exclusion criteria

Exclusion criteria: * Known hypersensitivity and/or serious adverse reactions to posaconazole or similar drugs * Concomitant anti-yeast/mould medication;

Design outcomes

Primary

MeasureTime frame
* Decrease in clone size * Decrease in activation status of CLL cells—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)